Results
104
Companys with strong funding and high growth potential
104 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 159.40 | -6.2% | -43.3% | SEK 14.1b | SEK 289.33 | PS47.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.15 | -4.2% | -32.4% | US$137.4m | US$8.65 | PS60.7x | E70.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €536.11 | 0.6% | 9.0% | €28.6b | €572.01 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.65 | 8.5% | 63.0% | US$1.6b | US$11.28 | PS7.5x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
BIOABS | SEK 173.90 | 0% | -37.8% | SEK 14.1b | SEK 315.65 | PS47.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €28.6b | €560.79 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
AKES.F | HK$8.73 | 2.9% | n/a | HK$58.4b | HK$8.52 | PS28.1x | E54.5% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 16.04 | -5.0% | -37.1% | SEK 14.1b | SEK 29.11 | PS47.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
0QW0 | €475.22 | -1.1% | 3.2% | €28.6b | €507.04 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €481.80 | 0% | 4.4% | €28.6b | €514.06 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BPMC | US$92.55 | 0.9% | 84.3% | US$5.9b | US$127.35 | PS16.2x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
0HOJ | US$93.83 | 1.3% | 87.4% | US$5.9b | US$129.11 | PS16.2x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$5.50 | -6.6% | -17.7% | US$326.8m | US$10.00 | PB3.3x | E62.3% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$9.64 | -4.9% | 111.5% | US$2.9b | US$24.49 | PS89x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.04 | -1.4% | -22.7% | US$73.1m | US$16.33 | PB8x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
SWTX | US$32.28 | -6.1% | 39.6% | US$2.4b | US$68.13 | PS27.8x | E75.6% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$4.26 | 1.9% | -13.2% | US$329.7m | US$20.60 | PS40.6x | E7.8% | n/a | Pharmaceuticals & Biotech | ||
BPMU.F | CHF 51.26 | 0% | n/a | CHF 563.6m | CHF 80.69 | PS3.8x | E34.4% | 0% | Pharmaceuticals & Biotech |